Currently out of the existing stock ratings of Jason Zemansky, 21 are a BUY (56.76%), 13 are a HOLD (35.14%), 3 are a SELL (8.11%).

Jason Zemansky

Work Performance Price Targets & Ratings Chart

Analyst Jason Zemansky, currently employed at BAML, carries an average stock price target met ratio of 42.41% that have a potential upside of 14.45% achieved within 59 days.

Jason Zemansky’s has documented 73 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on INSM, Insmed at 11-Jun-2025.

Wall Street Analyst Jason Zemansky

Analyst best performing recommendations are on ESPR (ESPERION THERAPEUTICS).
The best stock recommendation documented was for ESPR (ESPERION THERAPEUTICS) at 3/16/2023. The price target of $1.5 was fulfilled within 6 days with a profit of $0.32 (17.58%) receiving and performance score of 29.3.

Average potential price target upside

ALLK Allakos CYTK Cytokinetics ESPR Esperion Therapeutics INSM Insmed HOWL Werewolf Therapeutics RCUS Arcus Biosciences ALVR Allovir  KURA Kura Oncology SNDX Syndax Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$3

$1.79 (147.93%)

$3

9 months 7 days ago
(26-Sep-2024)

0/4 (0%)

$2.42 (417.24%)

Hold

$7

1 years 13 days ago
(20-Jun-2024)

1/3 (33.33%)

$0.45 (6.87%)

57

Sell

$1

$-0.21 (-17.36%)

$1.5

1 years 5 months 16 days ago
(17-Jan-2024)

6/6 (100%)

$-0.02 (-1.96%)

278

Buy

1 years 6 months 15 days ago
(18-Dec-2023)

1/1 (100%)

$32.69 (83.16%)

358

Buy

$9

$7.79 (643.80%)

2 years 1 months 22 days ago
(11-May-2023)

2/4 (50%)

$4.84 (116.35%)

178

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Jason Zemansky is most bullish on?

Potential upside of $20.84 has been obtained for CYTK (CYTOKINETICS)

Which stock is Jason Zemansky is most reserved on?

Potential downside of $9.05 has been obtained for RCUS (ARCUS BIOSCIENCES)

What Year was the first public recommendation made by Jason Zemansky?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?